Our method of predicting who will respond to therapy is cancer and therapy-specific. For example, we can accurately predict if a patient with melanoma will respond or otherwise to anti-PDL1 therapy. This approach can be customised for your molecule (whether it is a new chemical/ biological entity, or a known entity being repurposed for additional indications). We will work closely with you in your phase II trials or early phase III trials, where we will generate mutation sets that segregate responders from partial and non-responders. We will then use these mutation sets (of responders) to enroll patients into your phase III trials. Thus, the likelihood of patients who will respond to your therapy will considerably increase. The consequence of this approach will be that your phase III trials will be smaller, shorter, and less expensive, not to mention saving patent life. We will then continue to work with you to develop companion diagnostics to intelligently choose patients for your therapy. Furthermore, we can identify pathways and genes responsible for resistance to therapy (non-responders), allowing you to further develop targeted therapies to these novel targets to convert non-responders to responders.

Please write to us at partnering@trucansentinel.com for more information.